Therefore, although GSIs could be effective for treating Alzheimer’s disease with their inhibitory role of Aβ expression and accumulation, they have unwanted side effects of suppressing cell proliferation and survival by inhibiting Akt activation via PTEN elevation. This evidence concerns the gene PTEN and early-onset autosomal dominant Alzheimer disease.